重症肌无力的免疫修饰治疗

Immune modification therapy for myasthenia gravis

重症肌无力是一种主要由乙酰胆碱受体抗体介导累及神经-肌肉接头的自身免疫疾病.免疫修饰治疗可明显减少重症肌无力患者病死率并提升社会生活质量,但可用免疫抑制剂品种多样且均有剂量相关性的不良反应.目前国内外研究者对符合重症肌无力的免疫抑制剂选取、具体使用方法等问题尚无确切定论,因此有必要对重症肌无力常用免疫修饰治疗的临床应用进行综述,为临床医师在重症肌无力个体化免疫修饰治疗方面提供参考.

Myasthenia gravis is an autoimmune disease that is primarily mediated by acetylcholine receptor antibodies involving the neuromuscular junction.Immunomodification therapy can significantly reduce the mortality and improve the quality of social life of myasthenia gravis patients,but there are many kinds of immunosuppressants and dose-related adverse reactions.And so far,there is no definite conclusion on the selection and the specific use of immunosuppressants.This review summarized the clinical application of immunotherapy in myasthenia gravis,so as to provide a reference for clinicians in the treatment of myasthenia gravis.